Few people want to go into a nursing home, but doing so can be the right choice if you or a loved one is physically or cognitively disabled or recovering from surgery.
Risk Adjusted Net Present Value: What is the current valuation of Roivant Sciences’s Brepocitinib tosylate
The revenue for Brepocitinib tosylate is expected to reach an annual total of $256 mn by 2035 in the US based off GlobalData’s Expiry Model.